Your browser doesn't support javascript.
loading
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
Curry, M P; Tapper, E B; Bacon, B; Dieterich, D; Flamm, S L; Guest, L; Kowdley, K V; Lee, Y; Milligan, S; Tsai, N; Younossi, Z; Afdhal, N H.
Afiliación
  • Curry MP; Division of Gastroenterology and Hepatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Tapper EB; Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
  • Bacon B; Division of Gastroenterology/ Hepatology, Saint Louis University School of Medicine, Saint Louis, MO, USA.
  • Dieterich D; Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA.
  • Flamm SL; Division of Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Guest L; Trio Health Analytics, La Jolla, CA, USA.
  • Kowdley KV; Liver Care Network, Swedish Medical Center, Seattle, WA, USA.
  • Lee Y; Trio Health Analytics, La Jolla, CA, USA.
  • Milligan S; Trio Health Analytics, La Jolla, CA, USA.
  • Tsai N; The Liver Center, Queen's Medical Center, Honolulu, HI, USA.
  • Younossi Z; Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA.
  • Afdhal NH; Division of Gastroenterology and Hepatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Aliment Pharmacol Ther ; 46(5): 540-548, 2017 09.
Article en En | MEDLINE | ID: mdl-28691377
BACKGROUND: Treatment of genotype 1 hepatitis C virus (HCV) infection with combination direct acting anti-virals is associated with very high rates of sustained virological response (SVR). Daily combination of ledipasvir and sofosbuvir for 12 weeks is approved for the treatment of genotype 1 HCV patients, though noncirrhotic patients who are naïve to treatment with a baseline HCV RNA <6 million IU/mL can be treated for 8 weeks. This guidance stemmed from a post hoc analysis of the ION 3 clinical trial, which demonstrated similar SVR for patients treated with ledipasvir and sofosbuvir with or without ribavirin for 8 or 12 weeks. AIM: To compare the SVR for 8 weeks vs 12 weeks of ledipasvir and sofosbuvir in HCV infected patients in a real-world setting. METHODS: We performed an observational real-world cohort study of treatment success following 8 or 12 weeks of ledipasvir and sofosbuvir for treatment-naïve genotype 1 HCV patients. RESULTS: A total of 826 patients were treated for either 8 (n=252) or 12 weeks (n=574) with ledipasvir and sofosbuvir and achieved SVR rate of 95.3% and there was no statistical difference in SVR rates in the two groups irrespective of any clinical or virological variables. CONCLUSIONS: In treatment-naïve HCV genotype 1 patients, SVR was 95% in those treated for either 8 weeks or 12 weeks with ledipasvir and sofosbuvir. 8 week ledipasvir and sofosbuvir can reduce costs without compromising outcomes for those patients who qualify for such regimen.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Bencimidazoles / Hepatitis C Crónica / Fluorenos / Sofosbuvir Tipo de estudio: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Aliment Pharmacol Ther Asunto de la revista: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Bencimidazoles / Hepatitis C Crónica / Fluorenos / Sofosbuvir Tipo de estudio: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Aliment Pharmacol Ther Asunto de la revista: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido